Trabucchi E, Baratti C, Centemero A, Zuin M, Rizzitelli E, Colombo R
Pharmatherapeutica. 1986;4(9):541-50.
A controlled trial was carried out in patients with biliary dyskinesia to compare the effects of the new calmodulin-independent and antispastic drug tiropramide with those of imecromone. Forty patients were randomly divided into two groups, one treated with 300 mg tiropramide per day and the other with 1200 mg imecromone per day, both treatments lasting for 3 months. The results showed that tiropramide was significantly more effective in decreasing the number of attacks of pain and in improving pain and dyspepsia symptoms than imecromone. In subjects with delayed filling of the gall bladder during cholecystography, tiropramide but not imecromone was able to normalize the condition. These results confirm the antispastic synchronizing effect of tiropramide on the motor activity of the gall bladder and the sphincter of Oddi and indicate that it should be the drug of choice for treatment of motor disorders of the biliary tract.
对患有胆道运动障碍的患者进行了一项对照试验,以比较新型钙调蛋白非依赖性抗痉挛药物替罗哌胺与异美汀的效果。40名患者被随机分为两组,一组每天服用300毫克替罗哌胺,另一组每天服用1200毫克异美汀,两种治疗均持续3个月。结果显示,在减少疼痛发作次数以及改善疼痛和消化不良症状方面,替罗哌胺比异美汀显著更有效。在胆囊造影时胆囊充盈延迟的受试者中,替罗哌胺能够使病情恢复正常,而异美汀则不能。这些结果证实了替罗哌胺对胆囊和Oddi括约肌运动活性的抗痉挛同步作用,并表明它应是治疗胆道运动障碍的首选药物。